Risk factors
X4 Pharmaceuticals (XFOR) risk factors
Item 1A of every X4 Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors62 risks13 new14 dropped14 reworded
X4 Pharmaceuticals restructured operations, reducing headcount by 50% in September 2025 to focus on the 4WARD Phase 3 trial for mavorixafor in congenital neutropenia.
Filed Mar 17, 2026 - FY2024 10-K risk factors63 risks
X4 Pharmaceuticals faces substantial operating losses and requires additional capital to fund its commercialization and development programs.
Filed Mar 26, 2025